NAFLD (non-alcoholic fatty liver disease) is one of the most frequent chronic liver diseases worldwide. The metabolic factors associated with NAFLD are also determinants of liver disease progression in chronic HCV (hepatitis C virus) infection. It has been reported that, besides inducing hepatic fatty acid biosynthesis, LXR (liver X receptor) regulates a set of inflammatory genes. We aimed to evaluate the hepatic expression of LXRα and its lipogenic and inflammatory targets in 43 patients with NAFLD, 44 with chronic HCV infection and in 22 with histologically normal liver. Real-time PCR and Western blot analysis were used to determine hepatic expression levels of LXRα and related lipogenic and inflammatory mediators in the study population. We found that the LXRα gene and its lipogenic targets PPAR-γ (peroxisome-proliferator-activated receptor-γ ), SREBP (sterol-regulatory-element-binding protein)-1c, SREBP-2 and FAS (fatty acid synthase) were overexpressed in the liver of NAFLD and HCV patients who had steatosis. Moreover, upregulation of inflammatory genes, such as TNF (tumour necrosis factor)-α, IL (interleukin)-6, OPN (osteopontin), iNOS (inducible NO synthase), COX (cyclo-oxygenase)-2 and SOCS (suppressors of cytokine signalling)-3, was observed in NAFLD and HCV patients. Interestingly, TNF-α, IL-6 and osteopontin gene expression was lower in patients with steatohepatitis than in those with steatosis. In conclusion, hepatic expression of LXRα and its related lipogenic and inflammatory genes is abnormally increased in NAFLD and HCV patients with steatosis, suggesting a potential role of LXRα in the pathogenesis of hepatic steatosis in these chronic liver diseases.
INTRODUCTION
NAFLD (non-alcoholic fatty liver disease) is one of the most frequent causes of abnormal liver function and correlates with central adiposity, obesity, insulin resistance, the metabolic syndrome and Type 2 diabetes mellitus [1] . The pathological spectrum of NAFLD ranges from fatty liver (steatosis) to NASH (non-alcoholic steatohepatitis), advanced fibrosis, cirrhosis and even hepatocellular carcinoma [2] . Accumulation of excess triacylglycerol (triglyceride) in hepatocytes is necessary for the development of NAFLD. Fat either is delivered to hepatocytes in the form of free fatty acids bound to albumin or is synthesized de novo within hepatocytes [3] . In this regard, several lines of evidence indicate that hepatic activation of SREBP (sterol regulatory element-binding protein)-1c, together with other lipogenic or adipogenic transcription factors, is crucial for the development of fatty liver [4, 5] . Although the mechanisms involved in the transition from bland steatosis to NASH have not been fully established, so far, there is increasing evidence of the central role of non-triacylglycerol lipotoxicity in the pathogenesis of NASH [6] . In this hypothesis, the accumulation of triacylglycerol in the form of lipid droplets within the liver is not needed for the development of NASH, and in fact, it may be protective, whereas toxic metabolites derived from free fatty acids could lead to NASH by inducing endoplasmic reticulum stress, inflammation and liver cell death by apoptosis [7, 8] .
Hepatic steatosis is a common histologic feature in chronic HCV (hepatitis C virus) infection and has been reported to be associated with fibrosis [9] . HCV has been shown to alter host cell cholesterol/lipid metabolism and induce hepatic steatosis [10] . Furthermore, HCV proteins associate with mitochondria and endoplasmic reticulum and promote oxidative stress, increasing gene expression of oxidative stress-mediated inflammatory genes [11−13] .
LXRs (liver X receptors) are members of the nuclear hormone receptor superfamily that work as fatty acid-activated transcription factors [14] . Considerable evidence has emerged indicating that, besides to induce SREBP-1c-mediated hepatic fatty acid biosynthesis [4, 14] , LXRs repress in macrophages a set of inflammatory genes such as IL-6 (interleukin-6), iNOS (inducible NO synthase), COX (cyclo-oxygenase)-2 and OPN (osteopontin) [15, 16] . OPN is considered as a proinflammatory cytokine strongly associated with the early stages of development of NASH in animal models [17] . Although hepatic mRNA and protein levels of iNOS and COX-2 are increased in HCV patients [18, 19] , little is known, however, on the role of LXRs in the development of hepatic steatosis and inflammation in chronic HCV infection. On the basis of these data, it is conceivable that LXR may be a key regulator of hepatic lipogenesis and inflammation in NAFLD and HCV patients. In order to shed light on this hypothesis, we carried out the present study aimed to determine hepatic mRNA and protein levels of LXRα, and its related lipogenic and inflammatory targets in patients with NAFLD, chronic HCV infection and histologically NL (normal liver).
MATERIALS AND METHODS

Patients
This study comprised 87 non-diabetic patients with a clinical diagnosis of either NAFLD or chronic HCV infection who underwent liver biopsy for diagnostic purposes. Inclusion criteria for NAFLD patients were based on the absence of alcohol intake, the presence of biopsy-proven steatosis with/without necroinflammation and/or fibrosis, and a negative anti-HCV serum test. Patients with chronic HCV infection were included if they had serum anti-HCV and HCV RNA, persistently abnormal serum ALT (alanine aminotransferase) levels, liver histology findings compatible with chronic hepatitis and a negative history of alcohol consumption. In order to avoid bias depending on HCV genotype, all HCV patients included were infected by genotype 1. In addition, none of the HCV patients studied had ever received antiviral therapy. Patients with other potential causes of chronic liver disease or those receiving drug treatment for any chronic medical disorder were excluded.
We studied a further 22 patients with asymptomatic cholelithiasis from whom a liver biopsy was taken, during programmed laparoscopic cholecystectomy, as part of a study protocol and after signing a specific informed consent. All these subjects were otherwise healthy and had histologically normal liver, normal fasting glucose, cholesterol and triacylglycerols, normal AST (aspartate aminotransferase) and ALT and no evidence of viral infections (hepatitis B virus, HCV and HIV). In addition, none of these individuals drank alcohol.
The study was performed in agreement with the Declaration of Helsinki and with local and national laws. The Institution's Human Ethics Committee approved the study procedures, and written informed consent was obtained from all patients before inclusion in the study.
Clinical and laboratory assessment
After a 12-h overnight fast, clinical and anthropometric data for each patient were collected at the time of liver biopsy as well as venous blood samples to test hepatic enzymes and metabolic parameters by using a conventional automated analyser. Serum insulin was determined by a chemiluminescent microparticle immunoassay (ARCHITECT Insulin; Abbot Park). Insulin resistance was calculated by the HOMA-IR (homoeostasis model assessment of insulin resistance) [20] .
Antibodies against HCV and HIV as well as hepatitis B surface antigen were tested by immunoenzymatic assays (Murex). HCV RNA levels were quantified by real-time PCR (COBAS AmpliPrep/COBAS TaqMan HCV test; Roche Diagnostics). HCV genotyping was performed using a second generation line-probe hybridization assay [HCV genotype 2.0 assay (LiPA); Roche Diagnostics].
Liver tissue studies
Liver biopsies were divided into at least two pieces of a minimum length of 15 mm each. One of them was fixed in buffered formalin and used for routine histological staining, whereas the remaining pieces were immediately snap-frozen and stored in liquid nitrogen.
Histopathology assessment
Paraffin-embedded liver biopsy sections were evaluated under code by a single hepatopathologist blinded to the clinical data. Overall, steatosis was assessed as outlined by Brunt et al. [21] , and Kleiner's histological scoring system [22] was used to assess the grade of necroinflammation and the stage of fibrosis in NAFLD patients who were classified into two groups: those with simple steatosis [NAS (non-alcoholic steatosis)] and those with definite steatohepatitis (NASH). In the HCV group, the grade of necroinflammation and the stage of fibrosis were scored as proposed by Scheuer [23] . HCV patients were categorized into two groups, depending of the presence of steatosis.
Histological photomicrographs were acquired by using a high-resolution digital video camera (Nikon DXM 1200) connected to a light microscope (Nikon Eclipse E400) equipped with a planApocromatic ×20 objective.
Quantitative real-time PCR
Total RNA of liver biopsy samples from all patients was extracted by using a Trizol reagent (Life Technologies). First-standard cDNA was synthesized using a HighCapacity cDNA Archive Kit (Applied Biosystems). cDNA was amplified using multiplex real-time PCRs on a StepOne Plus (Applied Biosystems). TaqMan primers and probes were derived from the commercially available TaqMan ® Gene Expression Assays (Applied Biosystems) ( Table 1 ). Relative changes in gene expression levels were determined using the 2 − Ct method. The cycle number at which the transcripts were detectable (C t ) was normalized to the cycle number of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) detection, referred to as C t .
Western blot analysis
Protein extraction and Western blotting were performed as described previously [13] with modifications. Briefly, liver biopsy samples from all patients of each group were homogenized in a medium containing 0.25 mM • C with primary antibodies, i.e. rabbit polyclonal antibodies against LXRα (Abcam), SREBP-1c (Abcam), PPAR-γ (peroxisome-proliferator-activated receptor-γ ) (Santa Cruz Biotechnology), TNF-α (tumour necrosis factor-α) (Abcam) and iNOS (BIOMOL International) or a mouse monoclonal antibody against OPN (Abcam). Bound primary antibody was detected with HRP (horseradish peroxidase)-conjugated anti-rabbit or anti-mouse antibodies (DAKO), and blots were developed using an ECL (enhanced chemiluminescence) detection system (Amersham Pharmacia). The density of the specific bands was quantified with an imaging densitometer (Scion Image).
Statistical analysis
Categorical variables are presented as the frequency and percentage. Continuous variables are shown as means + − S.D. The baseline characteristics of the patients studied were compared by the Pearson χ 2 test for categorical variables and the unpaired Student's t test or Mann−Whitney U test for continuous variables. Data from real-time PCR and Western blotting were compared by using the Kruskal−Wallis ANOVA test. All statistical analysis were performed using SPSS version 15.0 software 
RESULTS
Patient characteristics
Characteristics of the study population are detailed in Tables 2 and 3 . To highlight, all patient groups were well matched in terms of age and sex distribution. NAS patients had significantly higher serum levels of triacylglycerols (P = 0.008) and γ -GT (γ -glutamyltransferase) (P = 0.037) than NL subjects. In NASH patients, the serum insulin levels and the mean HOMA-IR score were significantly higher than in NL individuals (P = 0.017 and P = 0.004 respectively), the higher serum levels of ALT being the only significant difference (P = 0.009) with respect to NAS patients. No significant differences were observed between HCV patient groups. At liver biopsy, the degree of steatosis was similar in NAS and NASH patients ( Figures 1A and 1B) . On the other hand, comparing HCV patients with or without steatosis ( Figures 1C and 1D ), no significant differences were found in the grade of necroinflammation and in the stage of fibrosis.
Hepatic expression of LXRα and related lipogenic genes is enhanced in NAFLD patients and in HCV patients with steatosis
When compared with NL, hepatic mRNA levels of LXRα and PPAR-γ were significantly increased in NAS (+114 % and +131 % respectively) and NASH (+131 % and +120 % respectively) (Figures 2A and 3A) . A significant induction in LXRα and PPAR-γ was also shown in HCV patients, being higher in those with steatosis (HCV, +41 %; HCV+NAS, +126 %; HCV, +44 %; and HCV+NAS, +132 % respectively compared with NL) (Figures 2A and 3A) . Hepatic mRNA levels of SREBP-1c were significantly higher in NAS (+81 %) and NASH (+124 %) than in NL ( Figure 3B ). Regarding HCV patients, hepatic mRNA levels of SREBP-1c were significantly increased with respect to NL only in those with steatosis (+165 %) ( Figure 3B ). We also found that hepatic mRNA levels of SREBP-2 were significantly higher in NAS (+190 %) and NASH (+80 %) than in NL ( Figure 3C ). Only HCV patients with steatosis had hepatic mRNA levels of SREBP-2 significantly more elevated than NL (+130 %) ( Figure 3C ). Hepatic gene expression of FAS (fatty acid synthase) showed a similar pattern to that observed for LXRα and PPAR-γ ( Figure 3D ). Hepatic content of LXRα, PPAR-γ and SREBP-1c proteins was significantly increased in NAS (+112, +86 and +126 % respectively) and NASH (+166, +89 and +176 % respectively) compared with NL ( Figures 2B and  4) . Noteworthy, protein amounts of LXRα and SREBP1c were significantly higher in liver biopsies from patients with NASH than in those with NAS ( Figures 2B and 4) . In addition, a significant increase in LXRα, PPAR-γ and SREBP-1c protein content was shown in HCV patients (+48, +46 and +43 %, respectively compared with NL), the highest LXRα, PPAR-γ and SREBP-1c levels being observed in HCV patients who had steatosis (+155, +276 and +191 % respectively compared with NL) (Figures 2B and 4) .
Hepatic expression of oxidative stress and inflammatory genes is up-regulated in NAFLD and HCV patients
Overexpression of CYP2E1 (cytochrome P450 2E1) leads to oxidative stress [24] . Thus we wanted to determine hepatic CYP2E1 gene expression in our study population. We found that CYP2E1 mRNA levels were significantly increased in the liver of patients with NAS (+74 %) and NASH (+72 %) with respect to NL ( Figure 5A ). Note, only HCV patients with steatosis had hepatic CYP2E1 mRNA levels significantly higher than NL (+105 %) ( Figure 5A ).
We analysed further hepatic mRNA levels of LXRrelated inflammatory genes such as TNF-α, IL-6, OPN, iNOS and COX-2. Intrahepatic OPN, TNF-α and IL-6 mRNA levels were significantly increased in NAS (+271, +123 and +300 % respectively) and NASH (+116, +105 and +188 % respectively) compared with NL (Figures 5B−5D ). Interestingly, OPN and IL-6 mRNA levels were significantly decreased in NASH ( − 57 and − 37 % respectively) with respect to NAS (Figures 5B and 5D ). However, no differences in the hepatic OPN and IL-6 mRNA levels between HCV patients with or without steatosis were observed ( Figures 5B and 5D ). In contrast, TNF-α mRNA levels were significantly higher in HCV patients with steatosis (+25 %) than in those without steatosis ( Figure 5C ). In addition, we found that hepatic suppressors of cytokine signalling SOCS (suppressors of cytokine signalling)-3 mRNA levels were significantly increased in NAS (+92 %) and NASH (+107 %) with respect to NL, the highest SOCS-3 mRNA levels being observed in HCV patients regardless of the presence of steatosis ( Figure 5E ). We also found that hepatic iNOS and COX-2 mRNA levels were significantly enhanced in NAS (+87 and +105 % respectively) and NASH (+102 % and +130 % respectively) as well as in HCV patients without steatosis (+221 and +524 % respectively) and with steatosis (+250 and +329 % respectively) compared with NL ( Figures 6A and 6B) .
On the other hand, a statistically significant increase in the hepatic abundance of OPN, TNF-α and iNOS proteins was observed in NAS (+137, +172 and +98 % respectively) and NASH (+105, +98 and +104 % respectively) with respect to NL (Figure 7) . Note, the hepatic content of OPN and TNF-α was significantly lower in NASH patients than in those with NAS ( Figure 7) . We also found a significant increase of OPN and iNOS proteins in HCV patients without
Figure 1 Liver biopsy features defining the study population
The degree of steatosis, largely macrovesicular, was similar in patients with steatosis (A) and in those with steatohepatitis (B). Portal and periportal mononuclear cell infiltrates were common findings in HCV patients without steatosis (C) and with steatosis (D), showing no significant differences between both patient groups (all photomicrographs show haematoxylin/eosin staining; original magnification ×200). Scale bar, 100 μm. steatosis (+309 and +137 % respectively) and with steatosis (+317 and +189 % respectively, compared with NL) Interestingly, in HCV patients, TNF-α protein content was highest when steatosis was present (HCV, +229 %; and HCV+NAS, +287 % compared with NL) (Figure 7 ).
DISCUSSION
There is experimental evidence that LXRα induces the expression of lipogenic genes, such as PPARγ and SREBP-1c, and down-regulates the expression of inflammatory genes, such as TNFα, IL-6 and OPN [14, 15] . The present study demonstrates that LXRα and its related lipogenic and inflammatory gene targets are up-regulated in liver biopsies from NALFD and HCV patients with steatosis. Given the key role of LXR signalling pathways in the cross-talk between lipogenesis and inflammation [15] , we propose a direct contribution of LXRα to the development of NAFLD as well as in HCV-associated steatosis.
LXRs belong to the nuclear hormone receptor family and are DNA-binding transcriptional regulators. LXRs form heterodimers with the RXR (retinoid X receptor)α and bind to target DNA sequences known as the LXRE (LXR-response element) [25] . There are two isoforms termed LXRα and LXRβ, both expressed in the liver among other locations [26] . In response to oxysterols, LXRs activate genes involved in reverse cholesterol transport and hepatic cholesterol metabolism [26] . Hepatic lipogenesis is generally induced by nuclear receptors such as PPAR-γ and LXRα [5, 14, 27] . These transcription factors increase the synthesis of fatty acids by either up-regulating SREBP-1c or directly binding to the promoters of some lipogenic genes, including FAS [4, 14, 28] . LXRα may play a role in enhancing lipogenesis in the liver of NAFLD patients, as previously described [29, 30] . In the current study, hepatic LXRα, PPAR-γ , SREBP-1c, SREBP-2 and FAS gene expression was significantly increased in NAFLD patients with respect to NL, and interestingly, the hepatic content of LXRα protein was significantly higher in NASH than in NAS. These findings suggest a steatogenic role for LXRα and its target lipogenic genes PPAR-γ , SREBP-1c, SREBP-2 and FAS. Different factors could induce hepatocyte LXR expression, such as saturated and unsaturated fatty acids, PPAR-γ , LXR agonists and lipid peroxidation products (by stimulating PPAR-γ ) [31, 32] . In turn, LXR increases the transcriptional activity and gene expression of PPAR-γ through the LXRE contained in its promoter region [32] . In addition, LXRα expression is controlled by an autoregulatory mechanism, since the human LXRα gene promoter contains three functional LXRE [25] . This mechanism may be responsible for the strong upregulation of LXRα in lipid-loaded hepatocytes. A novel finding of our study is that hepatic mRNA and protein levels of LXRα and its downstream lipogenic genes were abnormally increased in HCV patients who had steatosis. Mechanisms involved in HCV-induced steatosis seem to be mediated by HCV proteins, whose expression is associated with changes in lipogenic gene expression and/or the activity of lipogenic proteins and effects on mitochondrial oxidative function [10, 32] . Thus HCV core protein indirectly enhances the transcriptional activity of SREBP-1c, increasing the binding of LXRα/RXRα to LXRE as described in an in vivo model [33] . Accordingly, HCV core protein may play a crucial role in the development of hepatic steatosis by activating the LXRα signalling pathway in HCVinfected hepatocytes. In addition, HCV NS2 protein is able to induce the transcription of SREBP-1c and FAS, and this could be a contributing factor for HCVassociated steatosis [34] .
When an excess of fatty acids occurs in hepatocytes, CYP2E1 gene expression is induced initiating the process of lipid peroxidation [24] . In our present study, we found that hepatic mRNA levels of CYP2E1 were increased in NAFLD patients, as indicated previously [35] . Interestingly, CYP2E1 gene expression is also enhanced in HCV patients who had steatosis. The latter is in agreement with previous observations by Gochee et al. [11] , supporting the notion that hepatic CYP2E1 up-regulation is not a direct effect of HCV.
In fatty liver, distinct mechanisms such as oxidative stress, endoplasmic reticulum stress and hypoadiponectinaemia are able to activate a set of inflammatory pathways including secretion of inflammatory cytokines, such as TNF-α and IL-6 [36] . In particular, TNF-α promotes triacylglycerol accumulation and hepatic lipotoxicity, at least in part, by inducing hepatocyte lysosomal destabilization [37] . Our present results show an increased hepatic TNF-α, IL-6 and SOCS-3 gene expression in patients with NAFLD, whereas TNF-α protein and IL-6 mRNA levels were significantly lower in NASH than in NAS patients. These findings argue against a direct role of TNF-α and IL-6 as pathogenic mediators in NASH. However, many of the biological effects of TNF-α are mediated by IL-6, and experimental evidence exists showing that IL-6 induces hepatic SOCS-3 expression [38] . Since SOCS-3 promotes SREBP-1c expression and subsequent development of hepatic steatosis in mice [39] , our findings strongly suggest a key role for SOCS-3 in the development of steatosis in NAFLD patients. On the other hand, we also found an enhanced hepatic TNF-α and IL-6 gene expression in HCV patients, the highest TNF-α mRNA and protein levels being observed in those HCV patients who had steatosis. The latter is in agreement with previous observations [11] , suggesting that TNF-α may play an important role in the development of HCV-associated steatosis. Additionally, SOCS-3 gene expression is increased in HCV patients regardless of fat accumulation, as described previously in genotype 1 nonresponders subjects [40] .
Up-regulation of OPN gene expression has been implicated early in the development of NASH in a murine model [17] . In the present study, we found that OPN gene expression is markedly enhanced in NAS patients while significantly decreased in those with NASH, to a similar extent to that observed for TNF-α protein and IL-6 mRNA levels. Note that the highest LXRα protein levels were observed in the same NASH patients. As previously reported, this transcription factor might modulate hepatic inflammation by inhibiting TNF-α, IL-6 and OPN gene expression in Kupffer cells [15, 16, 41] . The mechanism underlying the repression of inflammatory genes by LXR is poorly understood. LXREs have not been identified in the proximal promoters of the repressed genes [15, 16] , indicating an indirect mechanism through the regulation of other transcription factors supporting gene transcription. Elucidating whether hepatic upregulation of LXRα occurs in hepatocytes or in Kupffer On the other hand, our present results also show that hepatic OPN gene expression is markedly increased in HCV patients regardless of the presence of steatosis, as previously indicated regarding SOCS-3 and IL-6 mRNA levels, favouring the hypothesis that inflammatory gene up-regulation might be a direct effect of HCV itself. In our present study, the highest LXRα protein levels observed in HCV-related steatosis is not accompanied by a repression of OPN, IL-6 and SOCS-3 gene expression. Thus there is no compelling evidence for a role of LXRα in modulating inflammation in HCV.
iNOS and COX-2 play an important role in development and progression of liver injury in NASH patients [42, 43] . The resuts of our present study confirm these observations and show further that hepatic iNOS and COX-2 gene expression is similarly increased in NAS and NASH, suggesting that hepatic iNOS and COX-2 up-regulation is an early event remaining unchanged in the course of NAFLD. In addition, we also found that hepatic iNOS gene expression is increased in HCV patients, the highest iNOS protein content being observed in HCV patients who had steatosis. These findings are in agreement with experimental evidence from our group indicating that HCV NS5A and core proteins are able to up-regulate iNOS gene expression [13] . An interesting finding of the present study is that hepatic COX-2 mRNA levels were significantly lower in HCV patients with steatosis than in those without fatty liver. There is experimental evidence that HCV core protein can induce COX-2 expression in human hepatocytes [19] , but whether fat accumulation may modulate COX-2 expression in HCV-infected hepatocytes, as suggested by our present results, deserves further investigation. In summary, taking into account all the findings showed in the present paper, it is conceivable that an enhanced LXR-induced hepatic lipogenesis may contribute to lipid accumulation in NAFLD and in chronic hepatitis C infection. However, our results do not support an anti-inflammatory effect of LXR and its dependent transcription factors (PPAR-γ ) in these chronic liver diseases, likely because their potential anti-inflammatory effects are overwhelmed by a number of distinct pro-inflammatory factors, such as lipotoxicity, endoplasmic reticulum stress and mitochondrial dysfunction in NAFLD, and apoptosis and virus-induced production of Th1 cytokines in chronic HCV infection.
In conclusion, the present study provides evidence that hepatic expression of inflammatory genes and LXRα lipogenic target genes are abnormally increased in NAFLD patients and in HCV patients with concomitant fatty liver. These results identify LXRα as a novel factor involved in the pathogenesis of hepatic steatosis in chronic liver diseases. Nevertheless, further experimental studies are needed to establish the specific relationship between LXR and lipogenic and inflammatory pathways in hepatocytes.
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